Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924104 | 0.84 | PTGDR2 (0.54) | PTGDR2MTNR1AMTNR1BSMN1; SMN2NPSR1 | |
| SCHEMBL6930798 | 0.84 | PTGDR2 (0.54) | PTGDR2MTNR1AMTNR1BSMN1; SMN2NPSR1 | |
| SCHEMBL24015488 | 0.80 | PTGDR2 (0.50) | PTGDR2MTNR1AMTNR1BSMN1; SMN2NPSR1 | |
| SCHEMBL7526613 | 0.80 | PTGDR2 (0.50) | PTGDR2MTNR1AMTNR1BSMN1; SMN2NPSR1 | |
| SCHEMBL15578425 | 0.78 | PTGDR2 (0.52) | PTGDR2MTNR1AMTNR1BSMN1; SMN2NPSR1 | |
| SCHEMBL13165574 | 0.77 | MTNR1A (0.47) | PTGDR2MTNR1AMTNR1BSMN1; SMN2NPSR1 | |
| SCHEMBL8457592 | 0.77 | PTGDR2 (0.48) | PTGDR2MTNR1AMTNR1BSMN1; SMN2NPSR1 | |
| SCHEMBL24011021 | 0.74 | PTGDR2 (0.46) | PTGDR2MTNR1AMTNR1BSMN1; SMN2NPSR1 | |
| SCHEMBL10246689 | 0.74 | PTGDR2 (0.46) | PTGDR2MTNR1AMTNR1BSMN1; SMN2NPSR1 | |
| SCHEMBL8503088 | 0.73 | PTGDR2 (0.45) | PTGDR2MTNR1AMTNR1BSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | PTGDR2 1286/4885MTNR1A 1225/4885MTNR1B 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.